細(xì)胞名稱

人胰腺癌細(xì)胞PaTu 8902

貨物編碼

BFN60870146

產(chǎn)品規(guī)格

T25培養(yǎng)瓶x1

1.5ml凍存管x2

細(xì)胞數(shù)量

1x10^6

1x10^6

保存溫度

37℃

-198℃

運輸方式

常溫保溫運輸

干冰運輸

安全等級

1

用途限制

僅供科研   3類

培養(yǎng)體系

DMEM高糖（HYCLONE SH30022.01)+10%FBS+1%三抗+200ug/ml IL2

培養(yǎng)溫度

37℃

二氧化碳濃度

5%

簡介

人胰腺癌細(xì)胞PaTu 8902 取自44歲女性。該細(xì)胞保藏于DSMZ。

注釋

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Part of: MD Anderson Cell Lines Project.

Part of: NCI RAS program mutant KRAS cell line panel.

Doubling time: ~25-40 hours (DSMZ).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Array-based CGH.

Omics: Deep exome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: Metabolome analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

基因突變

Heterozygous for EP300 p.Ser1650Tyr (6148C>A) (PubMed=10700188; CCLE; Cosmic-CLP).

Heterozygous for KRAS p.Gly12Val (c.35G>T) (ClinVar=VCV000012583) (CCLE; Cosmic-CLP).

Homozygous for TP53 p.Cys176Ser (c.526T>A) (ClinVar=VCV000376570) (PubMed=10700188; CCLE; Cosmic-CLP).

HLA信息

/

STR信息

Amelogenin X

CSF1PO 10,11

D3S1358 16,18

D5S818 11,12

D7S820 8,10

D8S1179 13

D13S317 11,12

D16S539 9,11

D18S51 15

D21S11 30

FGA 23

Penta D 11

Penta E 12,15

TH01 9.3

TPOX 8

vWA 18

參考文獻(xiàn)

PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051

 Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W., Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D., Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E., Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C., Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H., McCormick F.

 Differential effector engagement by oncogenic KRAS.

 Cell Rep. 22:1889-1902(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

 Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

 An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

 Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

 Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

 Next-generation characterization of the Cancer Cell Line Encyclopedia.

 Nature 569:503-508(2019)